S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.